ArticleCureus2024
Prostatic Adenocarcinoma in a Patient With a History of Cryptorchidism-Associated Hypogonadism: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is a prevalent malignancy often associated with advancing age and high androgen levels. Hypogonadism is characterized by low testosterone levels, and as prostate growth is androgen-dependent, this links elevated testosterone to increased prostate cancer risk. This rare presentation of a middle-aged man with the development of prostate cancer, following a history of congenital cryptorchidism and subsequent hypogonadism, challenges the conventional understanding of the role of testosterone in the development of prostate cancer. A gentleman in his late 60s, with a previous unilateral orchidectomy for suspected testicular cancer and 10 years of testosterone replacement therapy for hypogonadism, presented with an elevated prostate-specific antigen (PSA) level of 5.1 ng/mL. Digital rectal examination revealed a firm lobulated prostate, and MRI indicated a 15 mm PIRAD 4 (prostate imaging-reporting and data) lesion in the left peripheral zone. A trans-perineal biopsy confirmed a diagnosis of prostatic adenocarcinoma (Gleason score 3 + 3 = 6) with bilateral disease. To our knowledge, we are not aware of any previous literature reporting prostate cancer development in patients with cryptorchidism-associated hypogonadism. This report highlights the need for ongoing assessment of the long-term effects of testosterone replacement therapy in patients with a history of cryptorchidism and hypogonadism and the initiation or development of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.